Your basket is currently empty!
NICE rejects pembro+axitinib therapy for aRCC
Kidney cancer community strongly disagrees with NICE decision not to approve pembrolizumab with axitinib ...
News Archive
Axitinib
RCC combo approved on CDF
The UK's first as breakthrough kidney cancer combination treatment has been approved for immediate use through the ...
Researchers underscore efficacy of Pembrolizumab+Axitinib in treating advanced Rcc
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell ...
keytruda + axitinib cleared as first-line kidney cancer treatment in EU
Merck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of ...
Europe Adopts Pembrolizumab + Axitinib as 1st-Line Treatment for Advanced RCC
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), based in ...
Preliminary results for avelumab + axitinib..
.... as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an ...
New genetic cause of Wilms tumour discovered
Scientists have identified a new genetic cause of a childhood kidney cancer called Wilms tumour – revealing ...
NICE Recommendation of axitinib
Kidney Cancer UK welcomes the news today that the National Institute for Health and Care Excellence (NICE) are ...
NICE releases preliminary guidance to recommend Inlyta® (axitinib) for the treatment of advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) released preliminary guidance today in the ...
Axitinib (Inlyta) recommended as a second line kidney cancer treatment within NHS Scotland
Kidney Cancer Treatment recommended within NHS Scotland
Kidney Cancer Scotland is delighted at today’s news from ...
NICE denies patients with terminal kidney cancer access to Axitinib
Broadcaster James Whale MBE, Chairman of the Kidney Cancer UK and himself a kidney cancer survivor, commented that ...
